Compare stocks

Cosmo Pharmaceuticals N.V. is a specialty pharmaceutical company headquartered in Dublin, Ireland, with a focus on developing and manufacturing treatments for gastrointestinal diseases, specifically targeting the large intestine. The company's core products include therapies for ulcerative colitis, colon infections, and related areas. Cosmo's notable products, such as Lialda/Mezavant and Eleview, highlight its focus on advanced treatments that enhance colonic drug delivery and endoscopic visualization. The company has strategically concentrated its research and development to specialize in its therapeutic areas, leveraging its proprietary Methacrylate-Copolymer technology. Cosmo Pharmaceuticals also engages in partnerships to extend its market reach and continues to expand its influence globally through strategic collaborations and licensing agreements.

Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.